<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Med Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Med Case Rep</journal-id>
      <journal-title-group>
        <journal-title>Journal of Medical Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1752-1947</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25124389</article-id>
      <article-id pub-id-type="pmc">4149040</article-id>
      <article-id pub-id-type="publisher-id">1752-1947-8-275</article-id>
      <article-id pub-id-type="doi">10.1186/1752-1947-8-275</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Knez</surname>
            <given-names>Virginia M</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>Virginia.Knez@ucdenver.edu</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Barrow</surname>
            <given-names>Willis</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>wbarrow2@jhmi.edu</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Lucia</surname>
            <given-names>M Scott</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>Scott.Lucia@ucdenver.edu</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Wilson</surname>
            <given-names>Shandra</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>Shandra.Wilson@ucdenver.edu</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A5">
          <name>
            <surname>La Rosa</surname>
            <given-names>Francisco G</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>Francisco.LaRosa@ucdenver.edu</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Pathology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA</aff>
      <aff id="I2"><label>2</label>Department of Urologic Oncology, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <volume>8</volume>
      <fpage>275</fpage>
      <lpage>275</lpage>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>5</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Knez et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Knez et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.jmedicalcasereports.com/content/8/1/275"/>
      <abstract>
        <sec>
          <title>Introduction</title>
          <p>The occurrence of clear cell tumors in the bladder is not uncommon. Clear cell dysplasia is well-described and characterized by focal replacement of transitional mucosa by cells with abundant clear cytoplasm, nuclear enlargement, and a granular chromatin pattern. Clear cells can also be seen in clear cell adenocarcinoma, which is rare, comprising 0.5% to 2.0% of the reported bladder carcinomas. Other clear cell tumors found in the bladder to be considered in the differential diagnosis are tumors of M&#xFC;llerian origin and metastatic lesions, such as renal cell carcinoma, clear cell sarcoma, and malignant melanoma. Clear cell urothelial carcinoma is exceedingly rare, with only nine clinical cases described in the literature.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We report the case of a 75-year-old Caucasian man who presented with intermittent hematuria, in whom a bladder tumor was identified. A final histopathology examination of a cystoprostatectomy specimen revealed a pT3b, G3 urothelial carcinoma of clear cell type (&gt;90% clear cells) and a prostatic adenocarcinoma of Gleason grade 3+3 (score=6). The bladder tumor consisted of sheets of malignant cells with severe nuclear atypia and abundant clear cytoplasm; no glandular or tubular structures were identified. Tumor cells were periodic acid-Schiff positive and negative after diastase treatment; additional mucicarmine and oil red O stains were negative. Immunohistochemical stains showed the tumor cells positive for cytokeratin 7 (CK7), p63 (&gt;80% nuclei), p53 (about 30% nuclei), vimentin, E-cadherin, cluster of differentiation (CD10), and Ki-67 (&gt;70% nuclei). Stains for cell adhesion molecule 5.2 (CAM 5.2), CD117, cytokeratin 20 (CK20), human melanoma black 45 (HMB-45), paired box protein (PAX 8), placental alkaline phosphatase (PLAP), prostate specific antigen (PSA), renal cell carcinoma (RCC), cancer antigen 25 (CA25), leukocyte common antigen (LC), S-100 protein, and uroplakin III were all negative.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>The tumor marker profile was consistent with clear cell type carcinoma of urothelial origin. Within the differential diagnoses, we ruled out other possible tumor types such as urothelial carcinoma with focal clear cell differentiation, clear cell adenocarcinoma, M&#xFC;llerian tumors, and metastatic disease.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Clear cell</kwd>
        <kwd>Cancer</kwd>
        <kwd>Urinary bladder</kwd>
        <kwd>Urothelial carcinoma</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Urinary bladder carcinomas that differ on histology from typical urothelial carcinomas were reviewed by Young and Eble [<xref ref-type="bibr" rid="B1">1</xref>]. These tumors account for approximately 15% of all bladder carcinomas and fall into four major categories: variant forms of urothelial carcinoma, squamous cell carcinoma, adenocarcinoma, and undifferentiated carcinoma [<xref ref-type="bibr" rid="B1">1</xref>]. Variant forms of urothelial carcinoma include squamous and glandular differentiation, but these are only focal changes, with typical urothelial carcinoma seen elsewhere in the tumor [<xref ref-type="bibr" rid="B1">1</xref>].</p>
      <p>The identification of clear cell tumors in the bladder is not uncommon [<xref ref-type="bibr" rid="B2">2</xref>]. Clear cell dysplasia is well-described and characterized by focal replacement of transitional mucosa by cells with abundant clear cytoplasm, nuclear enlargement, and a granular chromatin pattern [<xref ref-type="bibr" rid="B3">3</xref>]. Clear cells can also be seen in clear cell adenocarcinoma, which is rare, comprising 0.5% to 2.0% of the reported bladder carcinomas [<xref ref-type="bibr" rid="B1">1</xref>]. The name clear cell adenocarcinoma is used because of the histologic similarity to clear cell adenocarcinomas of the female genital tract [<xref ref-type="bibr" rid="B1">1</xref>]. Clear cell urothelial carcinoma is exceedingly rare, with only nine clinical cases described in the literature [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Other clear cell tumors found in the bladder to be considered in the differential diagnosis are metastatic lesions, such as renal cell carcinoma or melanoma.</p>
      <p>We report the case of a male patient who underwent radical cystoprostatectomy for a urinary bladder tumor featuring rounded to polygonal cells with abundant clear cytoplasm, which deeply infiltrated the vesical wall. We discuss the morphologic features, immunohistochemical, and special staining pattern, and review the literature on clear cell urothelial carcinoma.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>Our patient was a 75-year-old Caucasian man with a history of intermittent hematuria for a few days the month preceding a cystoscopy. He was otherwise asymptomatic and denied bone pain, jaundice, hemoptysis, or weight loss. Of clinical relevance, he was a former smoker who quit 21 years ago and had been using smokeless tobacco for the last 16 years. His referring institution performed a cystoscopy revealing a bladder tumor and a biopsy that showed a high-grade urothelial carcinoma with widespread clear cell differentiation (&gt;80%), with severe necrosis, and extensive invasion into the muscularis propria. An ultrasound at the time showed a large urinary bladder mass with no evidence of extravesical disease, and mild right-sided hydronephrosis suggestive of obstruction of his distal right ureter. Because of an elevated serum creatinine of 1.6mg/dL, neoadjuvant chemotherapy was not attempted. A radical cystoprostatectomy was soon performed at our institution. On follow-up, his creatinine levels continued to be elevated and cisplatinum-based chemotherapy was further deferred. After one year of follow-up, our patient had no evidence of disease recurrence.</p>
      <p>The cystoprostatectomy specimen was fixed in 10% buffered formalin, and the prostate was dissected out for independent processing. Macroscopic examination showed a fungated and hemorrhagic urinary bladder mass arising from the mucosal surface, measuring 5.5&#xD7;5.0&#xD7;2.3cm, involving the inferior right lateral wall, and with near obliteration of the right ureteral orifice (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>). Representative sections of the bladder tumor were embedded in paraffin, sectioned at 5&#x3BC;m, and stained with hematoxylin-eosin. Microscopic examination revealed a tumor consisting of sheets and nodules of rounded to polygonal malignant cells with enlarged nuclei, prominent nucleoli, and abundant clear cytoplasm (&gt;90% clear cell differentiation) (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>A,B). No glandular differentiation or hobnail cells were observed. The tumor invaded through the full thickness of the muscularis propria (detrusor muscle) into the perivesical adipose tissue, approaching within 0.5mm of the perivesical serosal surface (pathology stage pT3b). Extensive necrosis accompanied by prominent acute inflammation was present. Lymphovascular invasion was identified. Focal carcinoma <italic>in situ</italic> was present in the adjacent surface urothelium. This tumor showed very similar histopathology to the prior bladder biopsy from the referring institution.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Macroscopic examination of the cystectomy specimen.</bold> Gross examination showing a fungated hemorrhagic mass measuring 5.5&#xD7;5.0&#xD7;2.3cm, involving the inferior right lateral wall, and with near obliteration of the right ureteral orifice (left). Cut section of the tumor shows full thickness invasion through the detrusor muscle and into the perivesical adipose tissue (right).</p>
        </caption>
        <graphic xlink:href="1752-1947-8-275-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Hematoxylin and eosin staining of the cystectomy specimen. (A)</bold> Sheets of clear cells can be seen invading through the muscularis propria into the perivesical adipose tissue (10&#xD7; objective). <bold>(B)</bold> Rounded to polygonal malignant cells with severe nuclear atypia, prominent nucleoli, and abundant, clear cytoplasm seen under a 40&#xD7; objective. <bold>(C)</bold> These cells were positive for periodic acid-Schiff, which <bold>(D)</bold> disappeared with diastase treatment. <bold>(E-H)</bold> Immunoperoxidase stains show tumor cells with strong positive membrane staining for CK7 <bold>(E)</bold>, approximately 30% nuclear staining for p53 antigen <bold>(F)</bold>, &gt;80% nuclear staining for p63 antigen <bold>(G)</bold>, and &gt;70% nuclear staining for Ki-67 (MIB-1) antigen <bold>(H)</bold>. Figures B through H at 40&#xD7; objective.</p>
        </caption>
        <graphic xlink:href="1752-1947-8-275-2"/>
      </fig>
      <p>The prostate gland revealed multifocal and bilateral prostatic adenocarcinoma, Gleason grade 3+3 (score=6), measuring 6mm in greatest dimension and involving &lt;5% of the prostate. There was focal extension of prostatic adenocarcinoma into the left posterior surgical margin (2mm in length).To characterize the content of the clear, vacuolated cytoplasm of the malignant cells in the bladder tumor, special histochemical stains were performed. The tumor cells were positive for periodic acid-Schiff (PAS) staining, which disappeared with diastase (PAS-D) treatment (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>C,D). The cells were negative for mucicarmine staining and for oil red O on frozen sections of the formalin-fixed tissue. This staining pattern confirmed the cells contained polysaccharides such as glycogen, as opposed to mucin or fat.</p>
      <p>Immunohistochemical stains were done with the following markers: Cytokeratin (CK) 7, CK20, Cell adhesion molecule (CAM) 5.2, p63, Uroplakin III, Vimentin, E-cadherin, p53, Cluster of differentiation (CD) 10, Paired box protein (PAX) 8, Renal cell carcinoma (RCC), CD117, Placental alkaline phosphatase (PLAP), S-100 protein, Human melanoma black (HMB) 45, Prostate Specific Antigen (PSA), Cancer Antigen 125 (CA-125), and Ki-67. Appropriate positive and negative controls were used. The tumor cells were positive for CK7 (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>E), p53 (approximately 30% nuclear, Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>F), p63 (&gt;80% nuclear, Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>G), Vimentin, E-cadherin (focal), CD10 (patchy), and Ki-67 (&gt;70% nuclear, Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>H). The tumor cells were negative for Cancer antigen 125, CAM 5.2, CD117, CK20, HMB-45, PAX 8, PLAP, Prostate specific antigen, S-100 protein, Uroplakin III, and RCC. Additionally, the cells were negative for Leukocyte common antigen, a test previously performed and reported by the referring institution. This tumor marker profile ruled out clear cell carcinoma of M&#xFC;llerian origin and other tissue origins and was most diagnostic of a primary urothelial origin. The immunostain and histochemical stain results are detailed in Table&#xA0;<xref ref-type="table" rid="T1">1</xref>.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Special immunoperoxidase and histochemical stains</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Antibody specificity</bold>
              </th>
              <th align="left">
                <bold>Tumor cell reactivity</bold>
              </th>
              <th align="left">
                <bold>Source</bold>
              </th>
              <th align="left">
                <bold>Clone</bold>
              </th>
              <th align="left">
                <bold>Positive controls</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">Cytokeratin 7<hr/></td>
              <td align="left" valign="bottom">Approx. 75%, cell membrane and cytoplasm<hr/></td>
              <td align="left" valign="bottom">Dako<hr/></td>
              <td align="left" valign="bottom">OV-TL12/30<hr/></td>
              <td align="left" valign="bottom">Breast carcinoma<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">p53<hr/></td>
              <td align="left" valign="bottom">Approx. 30%, nuclear<hr/></td>
              <td align="left" valign="bottom">Dako<hr/></td>
              <td align="left" valign="bottom">DO-7<hr/></td>
              <td align="left" valign="bottom">Breast cancer<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">p63<hr/></td>
              <td align="left" valign="bottom">&gt;80%, nuclear<hr/></td>
              <td align="left" valign="bottom">Biocare<hr/></td>
              <td align="left" valign="bottom">4A4<hr/></td>
              <td align="left" valign="bottom">Breast myoepithelial cells<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Vimentin<hr/></td>
              <td align="left" valign="bottom">Approx. 80%, cell membrane and cytoplasm<hr/></td>
              <td align="left" valign="bottom">Ventana<hr/></td>
              <td align="left" valign="bottom">3B4<hr/></td>
              <td align="left" valign="bottom">Salivary gland<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Ki-67<hr/></td>
              <td align="left" valign="bottom">&gt;70%, nuclear<hr/></td>
              <td align="left" valign="bottom">Ventana<hr/></td>
              <td align="left" valign="bottom">30-9<hr/></td>
              <td align="left" valign="bottom">Tonsil<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CD10<hr/></td>
              <td align="left" valign="bottom">Approx. 15%, cell membrane<hr/></td>
              <td align="left" valign="bottom">Cell Marque<hr/></td>
              <td align="left" valign="bottom">56C6<hr/></td>
              <td align="left" valign="bottom">Tonsil<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">E-cadherin<hr/></td>
              <td align="left" valign="bottom">Approx. 10%, cell membrane<hr/></td>
              <td align="left" valign="bottom">Cell Marque<hr/></td>
              <td align="left" valign="bottom">ECH-6<hr/></td>
              <td align="left" valign="bottom">Breast ductal carcinoma<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CA125<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Cell Marque<hr/></td>
              <td align="left" valign="bottom">OC1-25<hr/></td>
              <td align="left" valign="bottom">Ovarian carcinoma<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CAM 5.2<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Becton Dickinson<hr/></td>
              <td align="left" valign="bottom">CAM 5.2<hr/></td>
              <td align="left" valign="bottom">Cholangiocarcinoma<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">CD117<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Dako<hr/></td>
              <td align="left" valign="bottom">c-kit<hr/></td>
              <td align="left" valign="bottom">Gastrointestinal stromal<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Cytokeratin 20<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Biocare<hr/></td>
              <td align="left" valign="bottom">Ks 20.8<hr/></td>
              <td align="left" valign="bottom">Large intestinal epithelium<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">MAA<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Ventana<hr/></td>
              <td align="left" valign="bottom">HMB-45<hr/></td>
              <td align="left" valign="bottom">Melanoma<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">PAX 8<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Cell Marque<hr/></td>
              <td align="left" valign="bottom">MRQ-50<hr/></td>
              <td align="left" valign="bottom">Nonmucinous ovarian<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">PLAP<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Ventana<hr/></td>
              <td align="left" valign="bottom">NB10<hr/></td>
              <td align="left" valign="bottom">Placenta<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">PSA<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Ventana<hr/></td>
              <td align="left" valign="bottom">Rabbit polyc.<hr/></td>
              <td align="left" valign="bottom">Prostate<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">RCC<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Cell Marque<hr/></td>
              <td align="left" valign="bottom">PN-15<hr/></td>
              <td align="left" valign="bottom">Renal cell tubular epithelium<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">S-100 protein<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Ventana<hr/></td>
              <td align="left" valign="bottom">4C4.9<hr/></td>
              <td align="left" valign="bottom">Melanoma<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Uroplakin III<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Cell Marque<hr/></td>
              <td align="left" valign="bottom">SP73<hr/></td>
              <td align="left" valign="bottom">Urothelial carcinoma<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">
                <bold>Special histochemical stain</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">
                <bold>Reactivity</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">&#xA0;<hr/></td>
              <td align="left" valign="bottom">&#xA0;<hr/></td>
              <td align="left" valign="bottom">&#xA0;<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">PAS<hr/></td>
              <td align="left" valign="bottom">Positive cytoplasm<hr/></td>
              <td align="left" valign="bottom">Ventana<hr/></td>
              <td align="left" valign="bottom">&#xA0;<hr/></td>
              <td align="left" valign="bottom">Cirrhotic liver<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">PAS-diastase<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Ventana<hr/></td>
              <td align="left" valign="bottom">&#xA0;<hr/></td>
              <td align="left" valign="bottom">Cirrhotic liver<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Mucicarmine<hr/></td>
              <td align="left" valign="bottom">Negative<hr/></td>
              <td align="left" valign="bottom">Manual<hr/></td>
              <td align="left" valign="bottom">&#xA0;<hr/></td>
              <td align="left" valign="bottom">Small intestinal epithelium<hr/></td>
            </tr>
            <tr>
              <td align="left">Oil red O (frozen section)</td>
              <td align="left">Negative</td>
              <td align="left">Manual</td>
              <td align="left">&#xA0;</td>
              <td align="left">Perivesical adipose tissue</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>CA, Cancer antigen; CAM, Cell adhesion molecule; CD, Cluster of differentiation; MAA, melanoma-associated antigen; PAS, periodic acid-Schiff; PAX, Paired box protein; PLAP, Placental alkaline phosphatase; PSA, Prostate-specific antigen; RCC, Renal cell carcinoma.</p>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Urothelial carcinoma is the most common tumor arising in the urinary tract [<xref ref-type="bibr" rid="B4">4</xref>], and the most common variants have glandular or squamous differentiation [<xref ref-type="bibr" rid="B1">1</xref>]. Little is known, however, about urothelial carcinoma with predominantly clear cells, other than the few clinical cases reported previously, as listed in Table&#xA0;<xref ref-type="table" rid="T2">2</xref>[<xref ref-type="bibr" rid="B5">5</xref>].</p>
      <table-wrap position="float" id="T2">
        <label>Table 2</label>
        <caption>
          <p>Bibliographic references of case reports of clear cell urothelial carcinoma</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Patient</bold>
              </th>
              <th align="left">
                <bold>Clinical presentation</bold>
              </th>
              <th align="left">
                <bold>Pathology findings</bold>
              </th>
              <th align="left">
                <bold>Selected testing results</bold>
              </th>
              <th align="left">
                <bold>Additional history</bold>
              </th>
              <th align="left">
                <bold>Follow-up</bold>
              </th>
              <th align="left">
                <bold>Report</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td rowspan="5" align="left" valign="bottom">71 M<hr/></td>
              <td rowspan="5" align="left" valign="bottom">Painless hematuria<hr/></td>
              <td rowspan="5" align="left" valign="bottom">Left wall involvement into perivesical fat<hr/></td>
              <td align="left" valign="bottom">Glycogen positive<hr/></td>
              <td align="left" valign="bottom">Prostatic adenocarcinoma<hr/></td>
              <td rowspan="5" align="left" valign="bottom">Death after 20 months<hr/></td>
              <td align="left" valign="bottom">Kotliar <italic>et al.</italic>[<xref ref-type="bibr" rid="B6">6</xref>]<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Mucin negative<hr/></td>
              <td rowspan="4" align="left" valign="bottom">Gleason grade 2+3 (&gt;25%)<hr/></td>
              <td rowspan="4" align="left" valign="bottom">1995<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">PSA negative<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">PSAP negative<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">EM: no gland formation<hr/></td>
            </tr>
            <tr>
              <td rowspan="3" align="left" valign="bottom">58 F<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Dysuria and infected urethral cyst with pyuria<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Urethral involvement with invasion<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Glycogen positive<hr/></td>
              <td rowspan="3" align="left" valign="bottom">&#xA0;<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Data not available<hr/></td>
              <td align="left" valign="bottom">Kotliar <italic>et al.</italic>[<xref ref-type="bibr" rid="B6">6</xref>]<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="bottom">1995<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Mucin negative<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="bottom">70 F<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Intermittent, gross hematuria<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Right upper ureter stenosing lesion<hr/></td>
              <td align="left" valign="bottom">Glycogen positive<hr/></td>
              <td rowspan="2" align="left" valign="bottom">&#xA0;<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Alive at six months<hr/></td>
              <td align="left" valign="bottom">Braslis <italic>et al.</italic>[<xref ref-type="bibr" rid="B4">4</xref>]<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Mucin negative<hr/></td>
              <td align="left" valign="bottom">1997<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="bottom">70 M<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Frequency, urgency, anuria<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Red, irregular mucosa Invasion within 0.5mm of detrusor muscle.<hr/></td>
              <td rowspan="2" align="left" valign="bottom">&#xA0;<hr/></td>
              <td rowspan="2" align="left" valign="bottom">&#xA0;<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Data not available<hr/></td>
              <td align="left" valign="bottom">Braslis <italic>et al.</italic>[<xref ref-type="bibr" rid="B4">4</xref>]<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">1997<hr/></td>
            </tr>
            <tr>
              <td rowspan="3" align="left" valign="bottom">70 M<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Asymptomatic hematuria<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Left wall tumor, muscle invasive, treated with TURBt<hr/></td>
              <td rowspan="3" align="left" valign="bottom">&#xA0;<hr/></td>
              <td rowspan="3" align="left" valign="bottom">History of clear cell renal cell carcinoma, pulmonary metastasis<hr/></td>
              <td rowspan="2" align="left" valign="bottom">No recurrence after<hr/></td>
              <td align="left" valign="bottom">Yamashita <italic>et al.</italic>[<xref ref-type="bibr" rid="B7">7</xref>]<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="bottom">2006<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">seven months<hr/></td>
            </tr>
            <tr>
              <td rowspan="3" align="left" valign="bottom">69 F<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Gross hematuria<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Right wall tumor, treated with TURBt<hr/></td>
              <td rowspan="3" align="left" valign="bottom">&#xA0;<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Chronic renal failure, hemodialysis treatment<hr/></td>
              <td rowspan="2" align="left" valign="bottom">No recurrence after<hr/></td>
              <td align="left" valign="bottom">Isono <italic>et al.</italic>[<xref ref-type="bibr" rid="B13">13</xref>]<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="bottom">2010<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">20 months<hr/></td>
            </tr>
            <tr>
              <td rowspan="4" align="left" valign="bottom">82 M<hr/></td>
              <td rowspan="4" align="left" valign="bottom">Asymptomatic<hr/></td>
              <td rowspan="4" align="left" valign="bottom">Deep infiltration of muscularis propria<hr/></td>
              <td align="left" valign="bottom">GATA3+<hr/></td>
              <td rowspan="2" align="left" valign="bottom">History of clear cell renal cell carcinoma,<hr/></td>
              <td rowspan="4" align="left" valign="bottom">Alive at 12 months<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Rotellini <italic>et al.</italic>[<xref ref-type="bibr" rid="B2">2</xref>]<hr/></td>
            </tr>
            <tr>
              <td rowspan="3" align="left" valign="bottom">UroVysion fluorescence <italic>in situ</italic> hybridization<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="bottom">Furhman grade 2<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">2010<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="bottom">67 M<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Progressive lower urinary tract symptoms<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Bilateral ureteral stenosis due to muscle invasive mass in trigone, treated with TURBt<hr/></td>
              <td rowspan="2" align="left" valign="bottom">&#xA0;<hr/></td>
              <td rowspan="2" align="left" valign="bottom">&#xA0;<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Death at 14 weeks<hr/></td>
              <td align="left" valign="bottom">Kramer <italic>et al.</italic>[<xref ref-type="bibr" rid="B5">5</xref>]<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">2012<hr/></td>
            </tr>
            <tr>
              <td rowspan="3" align="left" valign="bottom">75 M<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Intermittent hematuria<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Right wall with near obliteration of ureter and invasion into fat<hr/></td>
              <td align="left" valign="bottom">Glycogen positive<hr/></td>
              <td align="left" valign="bottom">Prostatic adenocarcinoma<hr/></td>
              <td rowspan="3" align="left" valign="bottom">Alive at ten months<hr/></td>
              <td align="left" valign="bottom">Present case<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Mucin negative<hr/></td>
              <td rowspan="2" align="left" valign="bottom">Gleason grade 3+3 (&lt;5%)<hr/></td>
              <td rowspan="2" align="left" valign="bottom">2013<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Lipid negative<hr/></td>
            </tr>
            <tr>
              <td align="left">&#xA0;</td>
              <td align="left">&#xA0;</td>
              <td align="left">&#xA0;</td>
              <td align="left">PSA negative</td>
              <td align="left">&#xA0;</td>
              <td align="left">&#xA0;</td>
              <td align="left">&#xA0;</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>F, female; M, male; PSA, Prostate-specific antigen; PSAP, Prostatic acid phosphatase; TURBt, transurethral resection of bladder tumor. EM, electron microscopy.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>Although the presence of clear cells in otherwise typical urothelial carcinoma is not uncommon [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>], the tumor in this case had clear cells far in excess of what is normally seen in urothelial carcinoma. To the best of our knowledge, no study to date has shown that clear cell dysplasia progresses to clear cell urothelial carcinoma [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. &#x201C;In fact, the infrequent reporting of clear-cell transitional cell carcinoma, when compared with the relatively common observation of clear-cell dysplasia, makes this unlikely,&#x201D; per Braslis <italic>et al.</italic>[<xref ref-type="bibr" rid="B4">4</xref>].</p>
      <p>Regarding PAS staining, Braslis and colleagues similarly reported dense and spotty positivity for cytoplasmic glycogen in one of their cases of clear cell urothelial carcinoma (Table&#xA0;<xref ref-type="table" rid="T2">2</xref>) [<xref ref-type="bibr" rid="B4">4</xref>]. Normal urothelium contains glycogen, and positive reactivity of urothelial carcinomas for glycogen was explored by Kotliar and colleagues [<xref ref-type="bibr" rid="B6">6</xref>]. They selected 24 random urothelial carcinomas ranging from low-grade superficial papillary tumors to high-grade invasive tumors [<xref ref-type="bibr" rid="B6">6</xref>]. Approximately two thirds of tumors, despite their non-clear cytoplasm, showed varying degrees of PAS positivity that disappeared with diastase digestion (PAS-D). The overall apparent pattern of PAS/PAS-D reactivity correlated with tumor grade; in general, low-grade superficial urothelial cell carcinomas tended to have stronger diffuse staining, whereas poorly differentiated tumors tended to have negative or focal positivity [<xref ref-type="bibr" rid="B6">6</xref>].</p>
      <sec>
        <title>Differential diagnosis</title>
        <p>The finding of a clear cell carcinoma in the urinary tract usually implies the diagnosis of an adenocarcinoma [<xref ref-type="bibr" rid="B6">6</xref>]. Clear cell adenocarcinomas show a distinct predominance affecting the female urethra, although it may occur in men and in the urinary bladder [<xref ref-type="bibr" rid="B6">6</xref>]. These adenocarcinomas are characterized by tubules, cysts, papillae, or diffuse sheets of clear cells containing abundant, clear glycogen-rich cytoplasm [<xref ref-type="bibr" rid="B1">1</xref>]. The tumor cells lining the tubules and cysts may be cuboidal, hobnail, or flattened and usually show strong immunostaining for PAX 8 [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. A signet-ring cell type is observed in some cases and is distinguished by abundant intracytoplasmic mucin globules of varying size displacing the nucleus to the cell periphery [<xref ref-type="bibr" rid="B4">4</xref>]. By contrast, clear cell urothelial carcinomas, as observed in our case, do not show luminal formation or hobnail cells, and are mucin and PAX8 negative.</p>
        <p>The lipoid-cell variant of urothelial carcinoma could also be considered in the differential diagnosis. De Giorgi and colleagues described a bladder tumor featuring poorly differentiated, pleomorphic cells with nuclear pleomorphism and large, optically clear intracytoplasmic vacuoles imparting an adipocytic appearance [<xref ref-type="bibr" rid="B9">9</xref>]. Leroy and colleagues did stains on such tumors and found that mucin stain, alcian blue and PAS stains were negative, implying lipid content [<xref ref-type="bibr" rid="B10">10</xref>]. By contrast, clear cell urothelial carcinomas, as observed in our case (oil red O negative), show no lipid cytoplasmic content.</p>
        <p>Though less likely in the differential diagnoses, we could still consider a nephrogenic adenoma, especially the variant of a nephrogenic adenoma-like clear cell carcinoma. Herawi and colleagues did a study comparing clear cell adenocarcinoma, nephrogenic adenoma-like clear cell adenocarcinoma, and nephrogenic adenoma [<xref ref-type="bibr" rid="B11">11</xref>]. Features discriminating nephrogenic adenoma-like clear cell adenocarcinoma from nephrogenic adenoma included occasional clear cells, a prominent pleomorphism, and extensive muscular invasion [<xref ref-type="bibr" rid="B11">11</xref>]. The cytologic atypia of nephrogenic adenoma falls short of that seen in our case of clear cell urothelial carcinoma. In addition, nephrogenic adenoma has a low Ki-67 rate (0% to 5%) and is negative for p53, whereas in our case the Ki-67 and p53 nuclear expressions were very high (&gt;70% and approximately 30%, respectively) [<xref ref-type="bibr" rid="B11">11</xref>].</p>
        <p>The most likely clear cell metastatic disease to consider would be renal cell carcinoma. However, renal cell carcinoma metastasis to the bladder is very rare, with only approximately 30 cases reported in the literature [<xref ref-type="bibr" rid="B7">7</xref>]. On histology, renal cell carcinoma is frequently characterized by compact nests of cells with clear, abundant cytoplasm and delicate blood vessels [<xref ref-type="bibr" rid="B12">12</xref>]. This vascular network was not present in our case. In difficult cases, immunohistochemistry may be helpful. Renal cell carcinoma is typically negative for CK7 and CK20, but positive for RCC antigen, CAM 5.2, Vimentin, and PAX 8, in contrast to our case presented here [<xref ref-type="bibr" rid="B7">7</xref>].</p>
        <p>Clear cell carcinomas can also arise from other organs including prostate, lung, breast, uterus, ovary, and vagina [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. The latter sites are in females, and thus not applicable to this case. Prostatic origin however, is a consideration because our patient was discovered to have prostatic adenocarcinoma. Nevertheless, the prostate cancer observed in this case was low grade and focal (&lt;5% of the gland was involved). As described previously, no glandular formation was seen in the bladder tumor, the clear cell vacuoles were negative for lipid content (lipid material has been reported in prostatic adenocarcinoma [<xref ref-type="bibr" rid="B4">4</xref>]), and the tumor was p63 positive and PSA negative.</p>
        <p>Before identifying the tumor as a carcinoma, we also considered metastatic melanoma, clear cell sarcoma, and seminoma. These other possibilities were excluded by negative staining for S-100 protein, HMB-45, CD117, and PLAP, whereas positive staining for CK7 supported the diagnosis of carcinoma.</p>
      </sec>
      <sec>
        <title>Prognosis</title>
        <p>The clinical course of clear cell variant urothelial carcinoma of the bladder is currently not known due to the lack of a larger number of cases (Table&#xA0;<xref ref-type="table" rid="T2">2</xref>) [<xref ref-type="bibr" rid="B5">5</xref>]. Our patient in this case was alive ten months after initial presentation. In one of the cases reported by Braslis and colleagues, the longest patient survival was reported as at a six-month follow-up [<xref ref-type="bibr" rid="B4">4</xref>]. A less aggressive course was also reported in two patients who were treated with transurethral resection of the bladder tumor; even though one had detrusor muscle invasion, both were free from recurrence after seven and 20 months [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B13">13</xref>].</p>
        <p>In a case report by Kramer and colleagues, the urothelial clear cell carcinoma showed a very aggressive behavior with rapid local recurrence and development of peritoneal carcinomatosis from which the patient survived only 14 weeks after diagnosis [<xref ref-type="bibr" rid="B5">5</xref>]. A similar aggressive course was described by Kotliar and colleagues, in which a 71-year-old man underwent a radical cystoprostatectomy and two pelvic lymph nodes were found to be positive for metastatic disease; despite adjuvant chemotherapy, their patient died after 20 months [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>].</p>
      </sec>
      <sec>
        <title>Future directions</title>
        <p>Hepatocyte nuclear factor-1&#x3B2; was tested in clear cell adenocarcinomas of the bladder and urethra by Brimo and colleagues in 18 cases and was found to be a useful marker in differentiating clear cell adenocarcinomas from invasive high-grade urothelial carcinoma and other types of bladder adenocarcinomas [<xref ref-type="bibr" rid="B14">14</xref>]. It would be interesting to apply the marker to clear cell urothelial carcinoma to learn about the staining pattern of the tumor and, possibly, for diagnostic utility.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>The glycogen-rich, clear cell variant of urothelial carcinoma is an exceedingly rare tumor which we report in a case where malignant clear cells were far in excess of that seen in usual urothelial carcinomas. Immunohistochemical and histochemical stains helped exclude more common malignant tumors primary to the bladder, as well as metastatic lesions. Given the small number of reported cases, prognosis is not known; the continued report of these cases may eventually shed light on the biology and prognosis of these very rare tumors. Our patient is alive at the time of writing and constantly followed in our hospital system.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from our patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>CAM: Cell adhesion molecule; CD: Cluster of differentiation; CK: Cytokeratin; HMB: Human melanoma black; PAS: Periodic acid-Schiff; PAS-D: diastase; PAX: Paired box protein; PLAP: Placental alkaline phosphatase; PSA: Prostate-specific antigen; RCC: Renal cell carcinoma; CA: Cancer Antigen.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>VMK and FGLR were the major contributors in writing the manuscript. SW performed the surgical procedure. FGLR, MSL, and VMK performed the histological examination of the renal tumor, interpreted, and diagnosed the pathology findings. VMK and WBB prepared the tables. FGLR took the microscopic pictures and edited the figures. FGLR, MSL, and WBB reviewed the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>The authors acknowledge the valuable contribution of Mr David Davis, HT (ASCP) QIHC, Laboratory Manager, Surgical Pathology Histology Laboratory, University of Colorado Anschutz Medical Campus, and all his technical personnel who help to prepare the fine histological preparations.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Young</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Eble</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Unusual forms of carcinoma of the urinary bladder</article-title>
          <source>Hum Pathol</source>
          <year>1991</year>
          <volume>22</volume>
          <issue>10</issue>
          <fpage>948</fpage>
          <lpage>965</lpage>
          <pub-id pub-id-type="doi">10.1016/0046-8177(91)90003-8</pub-id>
          <pub-id pub-id-type="pmid">1842384</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rotellini</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fondi</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Paglierani</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Stomaci</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Raspollini</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Clear cell carcinoma of the bladder in a patient with a earlier clear cell renal cell carcinoma: a case report with morphologic, immunohistochemical, and cytogenetical analysis</article-title>
          <source>Appl Immunohistochem Mol Morphol</source>
          <year>2010</year>
          <volume>18</volume>
          <issue>4</issue>
          <fpage>396</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="doi">10.1097/PAI.0b013e3181d57dce</pub-id>
          <pub-id pub-id-type="pmid">20216403</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Berman</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Seidman</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yetter</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Clear cell dysplasia of the bladder. Report of a case with flow cytometric analysis</article-title>
          <source>Anal Quant Cytol Histol</source>
          <year>1991</year>
          <volume>13</volume>
          <issue>6</issue>
          <fpage>391</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="pmid">1807281</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Braslis</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Murphy</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Clear-cell transitional cell carcinoma</article-title>
          <source>Aust N Z J Surg</source>
          <year>1997</year>
          <volume>67</volume>
          <issue>12</issue>
          <fpage>906</fpage>
          <lpage>908</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1445-2197.1997.tb07625.x</pub-id>
          <pub-id pub-id-type="pmid">9451354</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kramer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Abbas</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pertschy</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Becker</surname>
            <given-names>JU</given-names>
          </name>
          <name>
            <surname>Kreipe</surname>
            <given-names>HH</given-names>
          </name>
          <name>
            <surname>Kuczyk</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Merseburger</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Tezval</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Clear-cell variant urothelial carcinoma of the bladder: a case report and review of the literature</article-title>
          <source>Rare Tumors</source>
          <year>2012</year>
          <volume>4</volume>
          <issue>4</issue>
          <fpage>e48</fpage>
          <pub-id pub-id-type="pmid">23372912</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kotliar</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wood</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Schaeffer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Oyasu</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Transitional cell carcinoma exhibiting clear cell features. A differential diagnosis for clear cell adenocarcinoma of the urinary tract</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>1995</year>
          <volume>119</volume>
          <issue>1</issue>
          <fpage>79</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="pmid">7802559</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Yamashita</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Yamaguchi</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Yuen</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Niwakawa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tobisu</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Urothelial carcinoma (clear cell variant) diagnosed with useful immunohistochemistry stain</article-title>
          <source>Int J Urol</source>
          <year>2006</year>
          <volume>13</volume>
          <issue>11</issue>
          <fpage>1448</fpage>
          <lpage>1450</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1442-2042.2006.01569.x</pub-id>
          <pub-id pub-id-type="pmid">17083402</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Whitworth</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Subhawong</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rosenthal</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ali</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Clear cell adenocarcinoma of the lower urinary tract: cytopathologic characteristics and differential diagnoses</article-title>
          <source>Cancer Cytopathol</source>
          <year>2012</year>
          <volume>120</volume>
          <issue>5</issue>
          <fpage>308</fpage>
          <lpage>312</lpage>
          <pub-id pub-id-type="doi">10.1002/cncy.21197</pub-id>
          <pub-id pub-id-type="pmid">22517612</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>De Giorgi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Pizzolitto</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Sacco</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Kocjancic</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Frea</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Falconieri</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Lipoid-cell variant of urothelial carcinoma: report of a new case of the urinary bladder</article-title>
          <source>Arch Ital Urol Androl</source>
          <year>2007</year>
          <volume>79</volume>
          <issue>4</issue>
          <fpage>173</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="pmid">18303737</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Leroy</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Gonzalez</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zini</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Aubert</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Lipoid-cell variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of five cases</article-title>
          <source>Am J Surg Pathol</source>
          <year>2007</year>
          <volume>31</volume>
          <issue>5</issue>
          <fpage>770</fpage>
          <lpage>773</lpage>
          <pub-id pub-id-type="doi">10.1097/01.pas.0000213410.48805.16</pub-id>
          <pub-id pub-id-type="pmid">17460462</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Herawi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Drew</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Epstein</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma</article-title>
          <source>Hum Pathol</source>
          <year>2010</year>
          <volume>41</volume>
          <issue>4</issue>
          <fpage>594</fpage>
          <lpage>601</lpage>
          <pub-id pub-id-type="doi">10.1016/j.humpath.2009.10.011</pub-id>
          <pub-id pub-id-type="pmid">20060152</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sim</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ro</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ordonez</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kee</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Ayala</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Metastatic renal cell carcinoma to the bladder: a clinicopathologic and immunohistochemical study</article-title>
          <source>Mod Pathol</source>
          <year>1999</year>
          <volume>12</volume>
          <issue>4</issue>
          <fpage>351</fpage>
          <lpage>355</lpage>
          <pub-id pub-id-type="pmid">10229498</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Isono</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Asano</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Shirotake</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tasaki</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Asakuma</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Satoh</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kimura</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Aida</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Urothelial carcinoma clear cell variant of the urinary bladder: a case report</article-title>
          <source>Hinyokika Kiyo</source>
          <year>2010</year>
          <volume>56</volume>
          <issue>3</issue>
          <fpage>163</fpage>
          <lpage>165</lpage>
          <comment>13</comment>
          <pub-id pub-id-type="pmid">20372045</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Brimo</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Herawi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sharma</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Netto</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Epstein</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Illei</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Hepatocyte nuclear factor-1&#x3B2; expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis</article-title>
          <source>Hum Pathol</source>
          <year>2011</year>
          <volume>42</volume>
          <issue>11</issue>
          <fpage>1613</fpage>
          <lpage>1619</lpage>
          <pub-id pub-id-type="doi">10.1016/j.humpath.2011.01.007</pub-id>
          <pub-id pub-id-type="pmid">21496868</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
